Quantcast
Last updated on April 16, 2014 at 21:22 EDT

Latest Intravenous immunoglobulin Stories

2008-07-31 12:00:23

U.S. medical scientists say a drug commonly prescribed to treat immunodeficiencies has shown promise as a treatment for Alzheimer's disease. Researchers at NewYork-Presbyterian Hospital and the Weill Cornell Medical Center announced the nine-month interim results of an ongoing Phase II double-blind, placebo-controlled clinical trial of gammagard intravenous immunoglobulin, or IGIV. Those results show significantly better global outcomes, cognitive performance and daily functioning in...

2008-07-31 09:01:26

LINCOLN, Neb., July 31 /PRNewswire/ -- Today, Grifols Biomat USA celebrates the grand opening of a new plasma donor center in Lincoln, Nebraska. The Lincoln center located on 2002 N Street is one of 60 Biomat USA center to be opened in the United States and the first in Nebraska. The plasma donated at the Lincoln center is then used by Biomat USA's parent company Grifols to produce life-saving medicines. Plasma is part of the blood that contains proteins and antibodies that are needed...

2008-07-30 18:00:54

CHICAGO, July 30 /PRNewswire-USNewswire/ -- Results from clinical trials of three potential Alzheimer's therapies raise hope for new and better treatments of the disease, according to data reported today at the 2008 Alzheimer's Association International Conference on Alzheimer's Disease (ICAD 2008) in Chicago. A related study showed that taking antidementia drugs appears to have a positive impact on extending lifespan in those with Alzheimer's. These reports included: Eighteen-month...

2008-07-30 18:00:22

To: NATIONAL EDITORS Contact: Alzheimers Association media line: +1-312-335-4078, media@alz.org; ICAD 2008 press room, July 27-31: +1-312-949-3253 - Plus, Taking Antidementia Drugs Extends Lifespan Three Years in Alzheimers - CHICAGO, July 30 /PRNewswire-USNewswire/ -- Results from clinical trials of three potential Alzheimers therapies raise hope for new and better treatments of the disease, according to data reported today at the 2008 Alzheimers Association International Conference...

2008-07-21 12:00:20

HOBOKEN, N.J. and FRISCO, Texas, July 21 /PRNewswire/ -- Octapharma USA, the largest privately owned, plasma fractionation company in the world, and ASD Healthcare, a part of AmerisourceBergen Corp., one of the world's largest pharmaceutical services companies, will jointly serve as the national title sponsors of the 2008 A-T Cure Tour. The national series of marathons and races benefits the A-T Children's Project, a non-profit organization focused on finding a cure or life-improving...

2007-11-11 03:00:07

By Boren, Todd Reyes, Carlos; Montenegro, Raul; Raimer, Karen Abstract Evan's syndrome is a rare hematological condition defined as immune thrombocytopenic purpura and hemolytic anemia. We describe herein a case of Evan's syndrome diagnosed in a term pregnancy that was refractory to primary therapeutic options. We also describe current treatment options in pregnancy and briefly discuss the pathophysiology of Evan's syndrome and perinatal outcome. Keywords: Pregnancy, Evan's syndrome,...

2007-05-18 06:00:37

By Florea, Anca V; Ionescu, Diana N; Melhem, Mona F Human parvovirus B19 is a single-stranded DNA virus with a predilection for infecting rapidly dividing cell lines, such as bone marrow erythroid progenitor cells. People with defective cell- mediated immunity (eg, severe combined immunodeficiency syndrome; acquired immunodeficiency syndrome; and patients receiving immunosuppressive therapy, ie, post organ transplant) can develop pure red cell aplasia, in which suppression of erythroid...

2006-07-19 00:10:49

WASHINGTON (Reuters) - Infusing human antibodies into people with Alzheimer's disease appears to slow disease progression and may even improve the patients' condition a little, researchers reported on Tuesday. Six of eight patients given intravenous immunoglobulin (IVIg) for 18 months appeared to develop better brain function, the team at New York-Presbyterian Hospital/Weill Cornell Medical Center told participants at a conference in Spain. "This study suggests that IVIg can exert...

2006-07-18 14:05:00

WASHINGTON (Reuters) - Infusing human antibodies into people with Alzheimer's disease appears to help stop the disease from getting worse and may even help the patients improve a little, researchers reported on Tuesday. Six of eight patients given intravenous immunoglobulin or IVIg for 18 months appeared to develop better brain function, the team at New York-Presbyterian Hospital/Weill Cornell Medical Center told a conference. "This study suggests that IVIg can exert long-term benefits for...

2006-02-13 16:18:20

By Megan Rauscher NEW YORK (Reuters Health) - Not all commercially available preparations of intravenous immunoglobulin (IVIG), an antibody therapy, are equally effective in children with Kawasaki disease, an immune system disorder that can cause fever, rash, and possible complications of the heart and brain, new research shows. The findings are based on a study of 437 children with the disease who were treated with one of four IVIG brands. "Physicians should be cautious when using...